1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 10,600 | 11,500 | 20:19 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.06. | Pharming Group N.V. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 04.06. | Pharming Group N.V.: Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja (leniolisib) to treat children aged 4 to 11 years with APDS | 135 | GlobeNewswire (Europe) | If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS), a rare primary immunodeficiency Supplemental... ► Artikel lesen | |
| 02.06. | Pharming Group N.V.: Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York | 379 | GlobeNewswire (Europe) | Leiden, the Netherlands, June 2, 2026: Pharming Group ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the 2026 Jefferies Global Healthcare Conference in New... ► Artikel lesen | |
| 28.05. | Pharming Group N.V.: Pharming Group announces results of 2026 Annual General Meeting of Shareholders | 994 | GlobeNewswire (Europe) | Leiden, the Netherlands, May 28, 2026: Pharming Group ("Pharming" or "the Company") (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that shareholders approved all proposals presented at... ► Artikel lesen | |
| 23.05. | Pharming Group Receives EU Approval For Joenja In Rare Immunodeficiency | 5 | RTTNews | ||
| PHARMING GROUP NV ADR Aktie jetzt für 0€ handeln | |||||
| 22.05. | Pharming Group N.V. - 6-K, Report of foreign issuer | 19 | SEC Filings | ||
| 22.05. | Pharming Group N.V.: European Commission grants marketing authorization to Pharming's Joenja (leniolisib) - the first approved treatment for APDS in the European Union | 399 | GlobeNewswire (Europe) | Joenja® (leniolisib) is first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3K,) syndrome (APDS), a rare primary immunodeficiency, in adult and pediatric... ► Artikel lesen | |
| 13.05. | Pharming Group: Umsatz im Q1 2026 sinkt wegen Herausforderungen bei RUCONEST | 11 | Investing.com Deutsch | ||
| 07.05. | Pharming GAAP EPS of $0.00 in-line, revenue of $72.4M misses by $19.67M | 11 | Seeking Alpha | ||
| 07.05. | Pharming Group N.V. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 07.05. | Pharming Group N.V.: Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders | 13 | GlobeNewswire (USA) | ||
| 07.05. | Pharming Group N.V.: Pharming Group reports first quarter 2026 financial results; on track for Joenja U.S. pediatric label expansion and launches in Japan and Europe in 2026 | 1.849 | GlobeNewswire (Europe) | First quarter 2026 total revenues were US$72.4 million, an 8% decrease compared to the first quarter 2025RUCONEST revenue was US$58.4 million, a 15% decrease compared to the first quarter 2025, mainly... ► Artikel lesen | |
| 23.04. | Pharming Group N.V.: Pharming Group to report first quarter 2026 financial results and provide business update on May 7 | 513 | GlobeNewswire (Europe) | Leiden, the Netherlands, April 23, 2026: Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial... ► Artikel lesen | |
| 16.04. | Pharming Group N.V. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 16.04. | Pharming Group N.V.: Pharming Group announces the 2026 Annual General Meeting of Shareholders | 392 | GlobeNewswire (Europe) | Leiden, the Netherlands, April 16, 2026: Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that the Company's 2026 Annual General Meeting... ► Artikel lesen | |
| 07.04. | Pharming Group N.V.: Pharming Group to participate in April investor conferences | 494 | GlobeNewswire (Europe) | Leiden, the Netherlands, April 7, 2026: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced that its management will participate in the following investor conferences... ► Artikel lesen | |
| 02.04. | Pharming Group N.V. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 02.04. | Pharming Group N.V. - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 02.04. | Pharming Group N.V.: Pharming Group announces the filing of its 2025 Annual Report and Form 20-F | 3 | GlobeNewswire (USA) | ||
| 27.03. | Pharming granted EU backing for rare immunodeficiency therapy | 2 | Seeking Alpha |
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,768 | +2,41 % | Evotec nach dem Absturz: Droht noch mehr Druck auf die Aktie? | Die Aktie von Evotec bleibt nach den jüngsten Geschäftszahlen unter Druck. Zwar wächst das operative Geschäft weiter, doch sinkende Gewinne und hohe Investitionen sorgen für Verunsicherung bei Anlegern.... ► Artikel lesen | |
| MODERNA | 43,850 | +2,25 % | Moderna und Uni Oxford starten Studie zu mRNA-Krebsimpfstoff | Moderna und die University of Oxford dürfen in Großbritannien eine klinische Studie zu einem mRNA-basierten Krebsimpfstoff beginnen. Die britische Arzneimittelbehörde MHRA hat die Phase-1/2-Studie zu... ► Artikel lesen | |
| VALNEVA | 2,302 | +0,74 % | Valneva: Das Signal das jetzt alles ändern könnte: Steht hier der Beginn einer neuen Rally? - Die Fakten auf einen Blick | ||
| PALATIN TECHNOLOGIES | 13,920 | +2,05 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| VIVOSIM LABS | 1,160 | -1,69 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders | RICHMOND, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that, after extensive consideration of the... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,500 | -1,69 % | Intellia Therapeutics, Inc. - 8-K, Current Report | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,182 | +0,98 % | Druck auf Pacific Biosciences nimmt zu: Warum die Geduld der Anleger auf eine harte Probe gestellt wird | Pacific Biosciences gerät zunehmend unter Druck: Die Aktie steht nach einer "significant downward revision of revenue guidance" und dem erzwungenen Aktienrückzug eines Großaktionärs im Fokus. Für Investoren... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,550 | -4,05 % | Arbutus Biopharma Corp - S-8, Securities to be offered to employees in employee benefit plans | ||
| ATAIBECKLEY | 3,320 | +1,22 % | H.C. Wainwright reiterates Buy on Atai stock, $25 target | ||
| XOMA ROYALTY | 35,800 | 0,00 % | Weekly Buzz: FDA Okays AstraZeneca's Saphnelo Pen, EC Clears Crinetics Pharmaceuticals' Acromegaly Drug, Soligenix Slumps, Ligand Snaps Up XOMA Royalty | BASEL (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals in the US and Europe, acquisitions, and a few trial halts, alongside positive data readouts spanning multiple therapeutic... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,270 | +0,44 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer | OCALA, Fla., June 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today reported positive progress in a mid-year update from the ongoing Phase 2 clinical... ► Artikel lesen | |
| NOVOCURE | 14,335 | -6,28 % | NovoCure Ltd - 8-K, Current Report | ||
| PHARMING | 1,123 | +0,58 % | Pharming Group N.V.: Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja (leniolisib) to treat children aged 4 to 11 years with APDS | If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS), a rare primary immunodeficiency Supplemental... ► Artikel lesen |
PHARMING GROUP NV ADR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 10,600 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMING GROUP NV ADR finden Sie auf Wallstreet Online.